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Abstract
Background: The detection of meningococcal outbreaks relies on serogrouping and epidemiologic definitions. Advances in
molecular epidemiology have improved the ability to distinguish unique Neisseria meningitidis strains, enabling the
classification of isolates into clones. Around 98% of meningococcal cases in the United States are believed to be sporadic.
Methods: Meningococcal isolates from 9 Active Bacterial Core surveillance sites throughout the United States from 2000
through 2005 were classified according to serogroup, multilocus sequence typing, and outer membrane protein (porA, porB,
and fetA) genotyping. Clones were defined as isolates that were indistinguishable according to this characterization. Case
data were aggregated to the census tract level and all non-singleton clones were assessed for non-random spatial and
temporal clustering using retrospective space-time analyses with a discrete Poisson probability model.
Results: Among 1,062 geocoded cases with available isolates, 438 unique clones were identified, 78 of which had $2
isolates. 702 cases were attributable to non-singleton clones, accounting for 66.0% of all geocoded cases. 32 statistically
significant clusters comprised of 107 cases (10.1% of all geocoded cases) were identified. Clusters had the following
attributes: included 2 to 11 cases; 1 day to 33 months duration; radius of 0 to 61.7 km; and attack rate of 0.7 to 57.8 cases
per 100,000 population. Serogroups represented among the clusters were: B (n = 12 clusters, 45 cases), C (n = 11 clusters, 27
cases), and Y (n = 9 clusters, 35 cases); 20 clusters (62.5%) were caused by serogroups represented in meningococcal
vaccines that are commercially available in the United States.
Conclusions: Around 10% of meningococcal disease cases in the U.S. could be assigned to a geotemporal cluster. Molecular
characterization of isolates, combined with geotemporal analysis, is a useful tool for understanding the spread of virulent
meningococcal clones and patterns of transmission in populations.
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Introduction
Neisseria meningitidis is an important cause of meningitis and other
serious bacterial infections globally. [1] In the U.S., over 98% of
meningococcal disease cases are considered to be sporadic, that is,
unrelated to other cases, but outbreaks also occur. [2,3]
Identification of meningococcal outbreaks typically relies on
serogrouping and epidemiologic definitions. [3,4] The incidence
of meningococcal disease in the U.S. is at historically low levels
[2].
Advances in objective, DNA sequence-based molecular epide-
miologic tools for N. meningitidis have enhanced the ability to
characterize this organism. Multilocus sequence typing (MLST) is
a standard molecular subtyping approach for determining genetic
lineage. [5] DNA sequencing of genes that encode outer
membrane proteins (OMPs) provides additional discriminatory
power among strains belonging to the same sequence type (STs).
[6,7] Together, MLST and OMP genotyping allow for the
classification of meningococcal isolates into specific clones, which
can be used to detect outbreaks and study patterns of spread
within populations. [8–10] In one study a spatial scan statistic was
used to identify 26 clusters of invasive meningococcal disease in
Germany using a clone definition based on serogroup, porA and
fetA typing [8].
We recently reported the population structure of invasive
meningococcal isolates throughout the United States. [11] The
purpose of the present study was to assess geotemporal clustering
patterns of specific meningococcal clones among the isolates
reported in that study to determine whether this approach could
identify both known and previously undetected clusters of
meningococcal disease.
Methods
Ethics Statement
The study was approved by the Johns Hopkins Bloomberg
School of Public Health, University of Pittsburgh, Emory
University, Georgia Department of Public Health, Vanderbilt
University School of Medicine and Tennessee Department of
Health institutional review boards. Institutional review board
approval was not required from the California, Colorado,
Connecticut, Minnesota, New York or Oregon Active Bacterial
Core surveillance sites because meningococcal disease is a
reportable condition and the activities fall under routine disease
surveillance authority.
Study Isolates and Determination of Serogroup
Invasive meningococcal study isolates were obtained through
active surveillance during the period of January 1, 2000-December
31, 2005 from 9 Active Bacterial Core surveillance (ABCs) sites.
ABCs, an active laboratory- and population-based surveillance
program for invasive bacterial pathogens, is a core component of
the Centers for Disease Control and Prevention (CDC) Emerging
Infections Programs Network. [12] ABCs defines a case as
isolation of N. meningitidis from a normally sterile site, such as
blood or cerebrospinal fluid, in a resident of an ABCs surveillance
area. [13,14] The CDC case definition of a serogroup C N.
meningitidis outbreak is $3 confirmed or probable cases in #3
months, resulting in a primary attack rate of $10 cases per
100,000 population among persons with a common organizational
affiliation or who live in the same community. [4] Although the
Advisory Committee on Immunization Practices (ACIP) defini-
tions and guidelines for the control and prevention of meningo-
coccal disease were initially developed for serogroup C meningitis,
the same principles are relevant for the control of cases
attributable to other vaccine-preventable N. meningitidis serogroups
including A, Y and W-135 [4].
Participating ABCs sites included the following areas: California
(three counties in the San Francisco Bay area), Colorado (5
counties in the Denver area), Connecticut, Georgia, Maryland,
Minnesota, New York (7 counties in the Rochester area and 8 in
the vicinity of Albany), Oregon, and Tennessee (11 urban counties
in the Nashville, Memphis, Knoxville and Chattanooga areas).
The population under surveillance in 2005 was approximately 38
million persons [15].
Laboratory work for this study was performed at the CDC and
the University of Pittsburgh. Serogrouping, MLST, and OMP
genotyping of porA VR1 and VR2, porB, and fetA VR were
performed as previously described. [7,11] Meningococcal clones
were classified according to serogroup, ST, and OMP (porA, porB,
and fetA) genotyping. To be considered as belonging to the same
clone, isolates had to be indistinguishable based on the results of
these assays.
Geotemporal Cluster Analysis
The methodology of cluster detection using SaTScan version
9.1.1 (Information Management Services, Inc., Silver Spring, MD,
and Martin Kulldorff, Boston, MA) is available on the Technical
Documentation page of the developer’s web site (www.satscan.
org/techdoc.html). [16–21] All analyses were conducted using a
dedicated personal computer with 4 GB of RAM. Case data were
aggregated to the census tract level and all non-singleton clones
were assessed for geotemporal clustering using retrospective space-
time analyses with a discrete Poisson probability model. Analyses
tested the hypothesis that the expected number of cases in each
census tract was proportional to its population size. The scan
identified clusters with high rates of N. meningitidis indicative of
non-random spatial and/or temporal distribution of cases.
Date of isolate culture was used to define the onset date of
illness. The units of time precision and time aggregation for all
analyses were days and months, respectively. The maximum
temporal window size for all analyses was 50% of the study period
(36 months), and the maximum spatial window 50% of the
population in each ABCs site. We chose these wide windows to
gain insight into the persistence of invasive meningococcal clones
over space and time. Our study aimed to assess the geotemporal
distribution of molecularly related clusters and, accordingly, the
selection of this long temporal window allowed identification of
clusters demonstrating a persistence of specific clones with
durations exceeding those of classically defined meningococcal
outbreaks. When the maximum window is set to 50% of the
population, both small and large clusters can be identified. The
statistical significance of each cluster was determined by 999
replications of Monte Carlo hypothesis testing and interpreted as
significant when p#0.05. Nine ABCs sites were analyzed
independently. To detect possible clustering across contiguous
ABCs sites, the following combined locations were also analyzed:
(1) the census tracts comprising metropolitan Chattanooga, TN,
and the state of Georgia; (2) the census tracts in the vicinity of
Albany, NY, and the state of Connecticut. ABCs sites were asked
to determine whether the clusters reported herein were identified
at the time they occurred, and whether the current study failed to
detect any previously known clusters.
Population and Geographic Data
Census 2000 geographic boundary files for states, counties and
census tracts participating in ABCs were obtained from the Census
Cartographic Boundary Files Collection of the U.S. Census
Geotemporal Analysis of N. meningitidis
PLOS ONE | www.plosone.org 2 December 2013 | Volume 8 | Issue 12 | e82048
Table 1. Case counts of non-singleton meningococcal clones, ranked by decreasing frequency.
Clone ID Serogroup Clone (CC: ST: porB: porA VR1, porA VR2: fetA) Count (% of total) ABCs site(s) with clone
1 Y 23:23:3-36: P1.5-2,10-1: F4-1 142 (13.4) CA,CO,CT,GA,MD,MN,NY,OR,TN
2 B 32:32:3-24: P1.7,16: F3-3 113 (10.6) CA,CO,CT,GA,MD,MN,OR,TN
3 Y 23:23:2-55: P1.5-1,2-2: F5-8 59 (5.6) CA,CO,CT,GA,MD,MN,NY,OR,TN
4 C 11:11:2-2: P1.5,2: F3-6 40 (3.8) CA,CO,CT,GA,MD,MN,NY,OR,TN
5 B 32:32:3-24: P1.7,16-20: F3-3 27 (2.5) CA,CO,GA,MD,MN,OR
6 C 11:11:2-2: P1.5,2: F1-30 22 (2.1) CO,CT,GA,MD,MN,OR,TN
7 B 162:162:3-73: P1.22,14: F5-9 16 (1.5) CA,GA,MD,MN,NY,TN
8 B 32:32:3-36: P1.7,16: F3-3 14 (1.3) OR
9 C 11:2962:2-75: P1.5-1,10-4: F3-6 14 (1.3) CA,GA,MD,NY,OR,TN
10 C 11:11:2-2: P1.22-1,14: F3-6 13 (1.2) GA,MD,MN,NY
11 B 32:3584:3-1: P1.7,16: F3-3 10 (0.9) OR
12 C 103:2006:2-110: P1.5-1,10-4: F3-9 10 (0.9) MN
13 C 11:11:2-2: P1.5-1,10-8: F3-6 10 (0.9) GA,MD,MN,NY
14 B 32:32:3-1: P1.7,16: F3-3 9 (0.8) CT,GA,MD,NY,OR
15 C 11:2962:2-88: P1.5-1,10-4: F3-6 9 (0.8) CO,GA,MD,MN,OR,TN
16 B 32:32:3-84: P1.7,16: F3-3 8 (0.8) GA,TN
17 Y 23:1625:2-55: P1.5-1,2-2: F5-8 7 (0.7) CT,GA,MD,MN,OR,TN
18 Y 23:23:3-36: P1.5,2: F4-1 7 (0.7) CA,CT,MN,OR,TN
19 B 41/44:136:3-107: P1.17,16-3: F5-5 6 (0.6) CA,CO,GA,NY,TN
20 C 11:2961:2-48: P1.5,2: F1-30 6 (0.6) MD,NY
21 B 35:35:3-39: P1.22-1,14: F4-1 5 (0.5) GA,MD,OR
22 B 41/44:154:3-1: P1.7-2,4: F1-5 5 (0.5) CA,CT,OR
23 C 11:11:2-73: P1.5,2: F3-6 5 (0.5) GA,MD,MN,NY
24 C 32:32:3-24: P1.7,16: F3-3 5 (0.5) MN,OR
25 W-135 22:22:2-23: P1.18-1,3: F4-1 5 (0.5) CO,MN,OR,TN
26 Y 167:1624:2-55: P1.5-1,10-4: F3-4 5 (0.5) CT,GA,NY,OR
27 B 32:32:3-133: P1.7,16-20: F3-3 4 (0.4) OR
28 B 41/44:4682:3-71: P1.22-1,14: F5-2 4 (0.4) CO,OR
29 C 11:11:2-2: P1.5,2: F1-5 4 (0.4) CA
30 C 11:11:2-2: P1.5-1,2-2: F3-6 4 (0.4) GA,NY,OR
31 Y 23:1625:2-141: P1.5-1,2-2: F5-8 4 (0.4) OR
32 Y 23:3582:2-55: P1.5-1,2-2: F5-8 4 (0.4) OR
33 B 32:32:3-1: P1.7,16-20: F3-3 3 (0.3) CT,MD
34 B 41/44:136:3-107: P1.17,16-23: F5-5 3 (0.3) CA,GA,TN
35 B 41/44:170:3-138: P1.21,16: F1-5 3 (0.3) OR
36 B 41/44:42:3-1: P1.7-2,4: F1-5 3 (0.3) CA
37 B 41/44:44:3-38: P1.7-1,1: F1-7 3 (0.3) NY,OR
38 B 41/44:44:3-45: P1.7-4,1: F1-7 3 (0.3) OR
39 B 41/44:5097:3-1: P1.7-2,4: F1-5 3 (0.3) TN
40 B 41/44:5111:3-45: P1.21,16: F1-7 3 (0.3) CT
41 C No CC:2048:3-16: P1.5,2: F3-6 3 (0.3) GA
42 C 11:11:2-2: P1.17,16-3: F3-6 3 (0.3) MD
43 C 11:11:2-2: P1.5,2: F3-3 3 (0.3) CA,OR
44 C 11:11:2-2: P1.5,2: F5-5 3 (0.3) OR
45 C 11:11:2-2: P1.5-1,2: F5-36 3 (0.3) MN
46 Y 23:1621:3-36: P1.5-2,10-1: F4-1 3 (0.3) MD
47 B No CC:2048:3-16: P1.12-1,16-8: F3-6 2 (0.2) CO,OR
48 B No CC:2875:2-136: porA Deletion: F4-1 2 (0.2) GA
49 B 254:254:3-223: P1.19,15: F1-5 2 (0.2) GA
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Bureau’s Geography Division. [22] Population and land area data
for ABCs surveillance sites were retrieved from the U.S. Census
Bureau Census 2000 Summary File (SF 1) 100-Percent Data Set.
[23] Using ArcGIS version 9.3.1 (ESRI, Inc., Redlands, CA), the
location of each case was geocoded using a perturbation
algorithm. The perturbation distance was designed to be an
inverse function of the population density in the respective census
tract. The purpose of the perturbation is to de-identify the location
of individual cases on a map. As a result, geocoded case locations
may exhibit displacement into an adjacent census tract in figures.
Analyses were conducted at the level of census tract with cases
aggregated to their true tract of residence. Census tract population
density (residents per km2) and attack rate (per 100,000
population) were calculated based on tract population and case
count.
Results
A total of 1,159 N. meningitidis isolates were obtained from cases
meeting the ABCs case definition between January 1, 2000 and
December 31, 2005. 1,062 (91.7%) of these cases were successfully
geocoded and included. The case counts by ABCs site were
California, 113 (10.6% of the total); Colorado, 49 (4.6%);
Connecticut, 82 (7.7%); Georgia 163 (15.4%); Maryland, 117
(11.0%); Minnesota, 126 (11.9%); New York, 75 (7.1%); Oregon,
267 (25.1%); and Tennessee, 70 (6.6%). Isolates were character-
ized by molecular subtyping into 438 unique clones, 78 (17.8%) of
which were non-singletons. Overall there were 702 cases
attributable to non-singleton clones, accounting for 66.0% of all
geocoded isolates. Molecular characteristics of the non-singletons,
ranked in decreasing order of frequency, are shown in Table 1.
Given the large number of distinct non-singleton clones
identified (116 distinct site/clone parings, with 7 separate analysis
files for each–one for each of the 6 study years, and a composite
2000–2005 file), parameterizing and executing the scans to
generate the results reported herein was time and computationally
intensive. Individual scans took anywhere from seconds to
upwards of 24 hours.
Thirty-two statistically significant clusters involving 107 cases
(10.1% of all geocoded isolates) attributable to 23 distinct clones
were identified (Table 2 and Figure 1) by independent analysis of
Table 1. Cont.
Clone ID Serogroup Clone (CC: ST: porB: porA VR1, porA VR2: fetA) Count (% of total) ABCs site(s) with clone
50 B 269:2974:3-113: P1.7-2,13-1: F5-7 2 (0.2) MD
51 B 32:1364:3-24: P1.7,16: F3-3 2 (0.2) CA,OR
52 B 32:32:3-107: P1.22-1,14: F3-3 2 (0.2) GA
53 B 32:32:3-1: P1.7,16-33: F3-3 2 (0.2) NY,OR
54 B 32:32:3-24: P1.7,16: F1-7 2 (0.2) OR
55 B 41/44:318:3-1: P1.7-2,4: F1-7 2 (0.2) MN
56 B 41/44:409:3-82: P1.18-1,34-2: F1-5 2 (0.2) CA,GA
57 B 41/44:41:3-172: P1.7-2,4: F1-5 2 (0.2) GA,TN
58 B 41/44:41:3-1: P1.7-2,4: F1-5 2 (0.2) CT
59 B 41/44:437:3-114: P1.22-1,14: F5-2 2 (0.2) MD
60 B 41/44:437:3-71: P1.22-1,14: F5-2 2 (0.2) GA
61 B 41/44:43:3-16: P1.19,15-1: F1-5 2 (0.2) GA,NY
62 B 41/44:4489:3-1: P1.7-2,4: F1-5 2 (0.2) GA
63 B 60:60:3-8: P1.22-1,14: F3-9 2 (0.2) MD
64 C 103:5837:2-22: P1.17,16-3: F1-18 2 (0.2) TN
65 C 11:11:2-2: P1.5,2: F3-1 2 (0.2) MD
66 C 11:11:2-2: P1.5,2: F4-12 2 (0.2) CA,OR
67 C 11:11:2-2: P1.5-2,10-2: F5-36 2 (0.2) MN
68 C 11:11:2-85: P1.22-1,14: F3-6 2 (0.2) MN
69 C 41/44:41:3-1: P1.7-2,4: F1-5 2 (0.2) CA
70 C 8:8:2-3: P1.5,2: F5-8 2 (0.2) MN
71 W-135 22:1476:2-23: P1.18-1,3: F4-1 2 (0.2) CO,OR
72 W-135 22:22:2-109: P1.18-1,3: F4-1 2 (0.2) CO
73 Y 22:1265:2-23: P1.18-1,3: F1-7 2 (0.2) GA
74 Y 23:183:3-53: P1.5-2,10-2: F4-1 2 (0.2) NY
75 Y 23:23:3-36: P1.5-2,10-12: F4-1 2 (0.2) MD,TN
76 Y 23:23:3-36: P1.5-2,10-29: F4-1 2 (0.2) GA,NY
77 Y 23:23:3-53: P1.5-2,10-2: F4-1 2 (0.2) GA,NY
78 Y 23:3587:3-36: P1.5-2,10-2: F4-1 2 (0.2) GA,OR
ST, sequence type; CC, clonal complex; VR, variable region; CA, California; CO, Colorado; CT, Connecticut; GA, Georgia; MD, Maryland; MN, Minnesota; NY, New York; OR,
Oregon; TN, Tennessee.
doi:10.1371/journal.pone.0082048.t001
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each ABCs site. Clusters were identified in all sites except
Colorado. Clusters ranged in duration from 1 day to 33 months.
19 clusters (59.4%) were composed of two cases and 13 (40.6%)
included 3 or more cases. Incidence ranged from 0.7 to 57.8 per
100,000, with 10 clusters (31.3%) having an attack rate of $10
cases per 100,000 population over the cluster time period.
Annualized incidence ranged from 1.1 to 693.6 cases per
100,000 population. The range of cluster radii was 0 to
61.7 km. Five clusters (15.6%) had radius of 0 km, indicating that
the involved cases occurred within a single census tract. Three of
the five zero-radius clusters (Clusters C, G and M) were previously
identified by the respective ABCs sites, and all were noted to be
case pairs among household members. Two zero-radius clusters
(Clusters S and CC), also comprised of case pairs, were previously
unidentified. No purely temporal clusters (those encompassing an
entire ABCs surveillance area) or purely spatial clusters (those with
a temporal window spanning the entire 72 month study period)
were identified.
In analyses of contiguous ABCs sites, one cluster (cluster GG)
caused by clone 16 included 7 cases in metropolitan Chattanooga,
TN and northwestern Georgia (radius = 21.9 km) that occurred
between January 22, 2005 and October 20, 2005 (Figure 1). In
single-site analyses, a 4-case cluster of Clone 16 (cluster E,
p = 0.001, radius = 19.3 km) was detected in Georgia and a 2-case
cluster in Tennessee (cluster EE, p = 0.011, radius = 6.1 km). The
cross-site analysis captured an additional case in Tennessee not
associated with the independently identified cluster in that state.
Eleven clusters (34.4% of all clusters) had previously been
identified by the ABCs sites, while 21 clusters (65.6%) had not
been identified. Cluster GG, which spanned the Georgia-
Tennessee border, was previously identified by local public health
practitioners. A cluster comprised of 2 cases occurring 1 week
apart among students at the same university was reported by
Connecticut but not detected in our analyses. These isolates were
identical by OMP genotyping but differed at a single MLST locus
(ST-1374 versus ST-40).
Three serogroups were represented among the clusters: B
(n = 12 clusters, 45 cases), C (n= 11 clusters, 27 cases) and Y (n= 9
clusters, 35 cases), indicating that 20 clusters (62.5%) were caused
by serogroups represented in meningococcal vaccines that are
available in the U.S. Although seven cases attributable to two
distinct serogroup W-135 clones were reported, no significant
serogroup W-135 N. meningitidis clusters were identified. Eleven
distinct serogroup B clones were responsible for 12 significant
clusters (37.5% of all clusters) in 5 states: Georgia (3), Maryland (1),
New York (1), Oregon (5), Tennessee (2), and an additional cross-
site cluster in Georgia/Tennessee. No cluster attributable to a
vaccine-preventable serogroup met the CDC definition of an
outbreak warranting consideration of vaccination for disease
control, and our analyses did not fail to detect any clusters that
prompted local health officials to consider vaccination as a control
strategy.
Sensitivity analyses were conducted to assess the impact of
alternate scanning window parameterizations. Spatial and tempo-
ral windows were varied from 25–50% and 25–90%, respectively.
The clusters detected differed negligibly for each permutation of
settings, so we elected to present the results for an intermediate set
of parameterizations with spatial and temporal windows each set
at 50%.
Discussion
We identified 32 meningococcal case clusters with non-random
spatial and temporal distribution, 21 (65.6%) of which had not
been previously identified. To our knowledge, this is the first study
of the geotemporal distribution of meningococcal clones causing
invasive disease in the United States. Our analyses highlight the
large diversity of circulating meningococcal clones in the U.S. and
the fact that most invasive meningococcal disease is caused by a
limited number of MLST-defined meningococcal lineages.
Importantly, 10.1% of cases belonged to a molecularly identified
cluster, which is higher than the proportion of cases identified in
outbreaks using traditional epidemiologic methods. [3] All five
clusters with a radius of 0 km (indicating that both cases in the pair
occurred in the same census tract) were associated with case pairs.
The attack rate and projected annualized incidence rate in the
affected census tracts ranged from 23.4 to 57.8 and 8.5 to 693.6
cases per 100,000 population, respectively. This highly non-
random spatial and temporal distribution of cases underscores the
importance of assessing the geotemporal distribution of as few as 2
isolates of the same clone. We did not detect any serogroup C
clusters that met the CDC definition of an outbreak warranting
consideration of vaccination. Assuming the ACIP serogroup C
outbreak definition thresholds, no clusters of serogroup Y disease
were detected that would prompt consideration of vaccination for
disease control. [4] This lack of geographically expansive clusters
comprised of large numbers of cases may be, in part, a reflection of
the historically low incidence of meningococcal disease in the
United States. [2] During the study period the national projection
for the annual incidence of meningococcal disease in the U.S.
decreased from 0.8 cases per 100,000 population (year 2000) to
0.35 cases per 100,000 population (2005), with a nadir of 0.31
cases per 100,000 in 2004 [24–29].
The finding of a cluster spanning the Georgia-Tennessee border
underscores the importance of looking across jurisdictional
boundaries and the use of a common definition of clone. Cross-
border spread has also been implicated in the increased incidence
of cases seen in the Aachen region of Germany and neighboring
Netherlands. [30] This edge effect was thought to explain the
excess number of districts surrounding Aachen which had
incidence rates higher than could be explained by complex
space-time conditional intensity modeling of Germany alone. [31]
In a study of 3,979 cases of meningococcal disease occurring from
2002–2008 in Niger, 15 clusters were identified. [32] Clusters
ranged in size from 9 to 558 cases, and exhibited a geographic
predominance in southeastern Niger. Movement across the border
between Niger and Nigeria in this region is common and
represents another example of this edge effect.
A previous spatiotemporal analysis of invasive meningococcal
disease in Germany used a molecular subtyping scheme similar to
ours with the exception that it did not include porB genotyping. [8]
This approach, applied to 1,616 cases, resulted in the identifica-
tion of 383 unique clones. 4.2% of cases were involved in a cluster,
and 76.9% of clusters involved only 2 patients. Although the
proportion of cases assigned to a cluster was lower in that study
than ours (10.1%), a similarly high number of detected clusters
included 2 patients (60% in our study).
Clone 2, a serogroup B strain, predominated in Oregon where
97 cases (85.8% of all Clone 2 isolates) were identified during the
study period. These isolates represented 36.3% of all invasive
Figure 1. Meningococcal clusters, by Active Bacterial Core surveillance site, 2000–2005. (A) California with San Francisco Bay area inset;
(B) Connecticut; (C) Georgia; (D) Maryland; (E) Minnesota; (F) New York; (G) Oregon; (H) Tennessee; (I) Georgia and Tennessee.
doi:10.1371/journal.pone.0082048.g001
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meningococcal cases in Oregon from 2000–2005. As reported
previously, the Oregon clone also caused disease in seven other
ABCs sites, but it was not implicated in any statistically significant
clusters in other states, confirming previous reports of its unique
epidemiologic behavior in Oregon [11].
The SaTScan methodology has several advantages for the study
of clustering among cases of invasive meningococcal disease. The
software is highly flexible and can be used for spatial, temporal or
space-time scan statistics, in either a retrospective or prospective
fashion. Scan parameters, including spatial and temporal windows
can be tailored to assess for specific types of endemic or epidemic
patterns of activity. We purposely set relatively large windows with
the goal of detecting patterns of transmission and disease beyond
what would be defined as a community outbreak. [4] Retrospec-
tive analyses aid the confirmation of previously detected clusters.
Most importantly, this methodology can be used to detect
associations between cases without a previously identified epide-
miological link. Prospective scans allow for the early detection of
related cases and may signal persistence of a clone in space or
time.
SaTScan allows the user to define clone characteristics, so
parameters can be tailored to complement the level of molecular
typing available. In this study, we used a highly conservative
definition of a clone, namely, identification by MLST and
genotyping of 3 OMP antigens. More clusters would have been
detected if porB genotyping results had been restricted to the level
of class 2 or 3 genotypes. If we had collapsed porB into class 2 or 3,
we would have identified 352 unique clones (a 19.6% decrease),
including 80 non-singletons. Using this classification, 790 cases
would be attributable to a non-singleton clone, accounting for
74.4% of geocoded isolates. With porB collapsed into class 2 or 3
and all other scan parameters unchanged, we would have detected
50 clusters, as opposed to the 32 detected with the stricter
definition used in this study. Consistent with the 2-case cluster
reported by Connecticut, in which epidemiologically related
isolates were indistinguishable except for a single locus difference
by MLST, a less-conservative definition of clone, while leading to
the detection of more clusters, would also have likely falsely
clustered unrelated cases. Regardless, the specific SaTScan settings
and definition of a clone can be tailored to the specific setting in
which this methodology is employed.
In summary, the SaTScan methodology is a flexible and
practical tool for the surveillance and analysis of meningococcal
disease. Geotemporal scan software, in conjunction with molecular
subtyping, can be used to study patterns of infectious disease
transmission, identify previously undetected clusters, and improve
understanding of the epidemiology of circulating molecular clones.
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